Navigation Links
Popular drugs for common male health problems can affect their sexual health
Date:3/7/2011

A new study published in The Journal of Sexual Medicine reveals that, for the first time, 5a-reductase inhibitors commonly used to treat urinary problems in patients with benign prostatic hyperplasia (BPH) and found in popular medications to treat hair loss, can produce, persistent erectile dysfunction (ED), depression and loss of libido, even after the medication has been discontinued.

Researchers led by Abdulmaged M. Traish, MBA, PhD, of Boston University School of Medicine, examined data reported in various clinical studies from the available literature concerning the side effects of the 5 alpha reductase inhibitors, finasteride and dutasteride.

Prolonged adverse side effects on sexual function, such as ED, depression and diminished libido, were reported by a subset of men. Drug-related reduction in libido occurred in 4.2% and 1.8% of patients in the dutasteride and placebo groups, respectively. Reduced ejaculation and semen volume were also reported and in some patients, these drugs were associated with depression.

"For these reasons, patients and doctors are urged to discuss these issues openly and candidly and assess the risk benefit ratio prior to commencing therapy with 5a-reductase inhibitors" Dr. Traish notes.

Dr. Irwin Goldstein, editor-in-chief of The Journal of Sexual Medicine, has seen and evaluated numerous such patients. He further explained the importance of this study. "Young men are being prescribed 5 alpha reductase inhibitors as hair loss treatments that may negatively impact their sexual life, possibly for a prolonged time after stopping the medication. Older men with symptoms of lower urinary tract symptoms or fearful of prostate cancer, now have to deal with new onset sexual and mental health problems. The growing use of 5 alpha reductase inhibitors is causing concerns." Clearly more research is needed to better understand the basis for these drug-associated side effects but it is evident that 5 alpha reductase inhibitors prevent the synthesis of very critical central nervous system neurosteroids and lower a very important sex steroid hormone, dihydrotestosterone.


'/>"/>

Contact: Amy Molnar
healthnews@wiley.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Popular Bone Drugs Linked to Reduced Colon Cancer Risk
2. Bullying May Accompany Drive to Be Popular
3. Zebrafish popular with researchers
4. Tanning Beds Still Popular Despite Skin Cancer Risk
5. Popular Mechanics breakthrough awardees announced
6. Popular prostate cancer treatment associated with bone decay
7. New guideline finds no evidence for a popular back procedure
8. Expert Panel Links Popular Bone Drugs to Rare Fracture
9. Popular diabetes drugs associated with fractures in type 2 diabetic patients
10. New research finds no evidence that popular slimming supplements facilitate weight loss
11. Iceland -- Working on its Popularity for Travellers, Iceland ProTravel Supports Ad Campaign "Inspired by Iceland"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... TruClinic Inc. announced ... company based in New York. , “Ensuring an intuitive, user-friendly patient experience is ... Those two fundamental reasons are the reasons this acquisition is an obvious one,” ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... has challenges as they transition from military to civilian life. Body image dissatisfaction ... million who experience poorer health and greater occurrence of chronic mental health conditions ...
(Date:2/27/2017)... ... 27, 2017 , ... Bo Chen, PhD is the recipient of the 2017 ... during the Plenary Session at ASLMS 2017, the Annual Conference of the American Society ... April 5-9, 2017. , During the Plenary Session on April 7, Dr. Chen ...
(Date:2/27/2017)... ... 2017 , ... Hotze Health & Wellness Center (HHWC), a ... New Guest Director. , Brandl is a dynamic and influential executive leader ... his professional career at Omnium Worldwide, now known as West Corporation, and handled ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... Shamanic Healing and Spiritual Awakening, is happy to announce her “Spring Rejuvenation ... and body, these individual customized retreats offer the winter-weary soul an excellent opportunity ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... AMSTERDAM , Feb. 27, 2017   ... AEX: PHIA), a global leader in health technology, ... and Drug Administration (FDA) to market its ElastQ ... EPIQ family of ultrasound systems. ElastQ Imaging enables ... stiffness, which is essential for the diagnosis of ...
(Date:2/27/2017)...  Infinity Pharmaceuticals, Inc. (NASDAQ: INFI ) ... th Annual Healthcare Conference on Monday, March 6, ... MA. A live webcast of Infinity,s presentation ... website at www.infi.com , and will be available ... Infinity,Infinity is an innovative biopharmaceutical company dedicated to advancing ...
(Date:2/27/2017)... A recent research report published by Grand View Research, ... to reach a value of $55.8 billion by 2025. Earlier in ... have legalized marijuana for medical uses. In 2016, states such as ... North Dakota , Ohio and ... in medical applications such as chemotherapies and pain management. The growing ...
Breaking Medicine Technology: